PPP1R15B: A Potential Drug Target and Biomarker for Protein Phosphatase 1 Regulatory Subunit 15B

Target Name: PPP1R15B

NCBI ID: G84919

PPP1R15B

PPP1R15B: A Potential Drug Target and Biomarker for Protein Phosphatase 1 Regulatory Subunit 15B

Introduction

Protein phosphatases are a family of enzymes that regulate various cellular processes, including cell signaling, DNA replication, and metabolism. One of the best-known protein phosphatases is Protein phosphatase 1 (PPI1), also known as PPP1R15B, which is a key regulator of the phosphatidylinositol (PI) signaling pathway. PPI1 plays a crucial role in cell signaling, particularly in the regulation of cell adhesion, migration, and invasion. The dysfunction of PPI1 has been implicated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Recent studies have identified PPI1 as a potential drug target and biomarker for various diseases. The high-throughput screening (HTS) screening approach has led to the identification of small molecules that can inhibit the activity of PPI1. One of these compounds, PPP1R15B (Protein phosphatase 1 regulatory subunit 15B), has shown promise in preclinical studies as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

PPP1R15B: A Putative Drug Target

The PI signaling pathway is a well-established target for drug development, and PPI1 is a prime candidate for drug targeting due to its unique structure and function. PPI1 is a 22kDa protein that contains a catalytic active site, a regulatory region, and a C -terminal hypervariable region (HVR). The catalytic active site is the site of phosphorylation, while the regulatory region plays a role in regulating the activity of the enzyme. The C-terminal HVR is involved in the regulation of the activity of PPI1 and has been implicated in various cellular processes.

PPI1 has been implicated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, PPI1 has been shown to be overexpressed in various cancer types, including breast, ovarian, and colorectal cancers. Additionally, PPI1 has been implicated in neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Furthermore, PPI1 has been implicated in autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis.

PPP1R15B: A Potential Biomarker

The identification of PPI1 as a potential drug target and biomarker for various diseases has led to the search for small molecules that can inhibit its activity. One of these compounds, PPP1R15B, has shown promise in preclinical studies as a potential inhibitor of PPI1.

PPP1R15B is a 21kDa protein that contains a catalytic active site, a regulatory region, and a C-terminal HVR. The catalytic active site is the site of phosphorylation, while the regulatory region plays a role in regulating the activity of the enzyme. The C-terminal HVR is involved in the regulation of the activity of PPI1 and has been shown to play a role in various cellular processes.

In preclinical studies, PPP1R15B has been shown to be a potential inhibitor of PPI1. The activity of PPP1R15B was inhibited by various chemical compounds, including inhibitors of the catalytic active site, the regulatory region, and the C-terminal HVR. Additionally , PPP1R15B was shown to reduce the phosphorylation level of PPI1 in various cell types, including cancer cells, neuroblastoma cells, and human keratinocytes.

Conclusion

PPI1 is a protein that plays a crucial role in

Protein Name: Protein Phosphatase 1 Regulatory Subunit 15B

Functions: Maintains low levels of EIF2S1 phosphorylation in unstressed cells by promoting its dephosphorylation by PP1

The "PPP1R15B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PPP1R15B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets